Navigation Links
Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
Date:12/7/2011

JACKSONVILLE, Fla. -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida. Their report, published online in Gynecologic Oncology, suggests that this combination (ixabepilone and sunitinib), might offer a much needed treatment option for women with advanced ovarian cancer. When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it.

"Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance which may be what this combination of agents is doing would be a boon to treatment of this difficult cancer," says study co-author Gerardo Colon-Otero, M.D., a hematologist-oncologist who cares for ovarian cancer patients.

The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. The study's senior investigator, cancer biologist John Copland, Ph.D., has identified RhoB as a key modulator for drug response in other tumor types, but says its role in ovarian cancer was unknown before this study.

"Now we find that with this combination of drugs, RhoB is increased and cells die," he says.

The study was possible because Dr. Copland and his laboratory colleagues, including co-author Laura Marlow, created and characterized two new ovarian laboratory cell lines. They were derived from tumor tissue specimens taken from a patient with metastatic cancer whose tumors had stopped responding to multiple chemotherapy drugs.

Dr. Colon-Otero suggested trying the two drugs on the new cells lines. Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.

Prakash Vishnu, M.D., a former fellow at Mayo Clinic in Florida who is now at the Floyd and Delores Jones Cancer Institute in Virginia Mason Medical Center, Seattle, is the first author of the article and led the study under the mentorship of Drs. Colon-Otero and Copland. He found that in both cell lines, cell kill was significantly greater with the combination than use of either drug alone. For example, in chemotherapy-resistant lines (where this potential combination therapy will most likely be used), ixabepilone alone killed up to 30 percent of cells, and the rate for suntinib was up to 10 percent. When the agents were used together, the kill rate was 70 percent.

Dr. Copland said that RhoB is a potential biomarker that may help identify patients who might benefit from such combination therapy.


'/>"/>
Contact: Kevin Punsky
Punsky.Kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Pycnogenol® found to improve memory and test scores in college students in new clinical trial
2. American Society of Clinical Oncology issues annual report on progress against cancer
3. Novocure establishes initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields Therapy
4. Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
5. Newly established neuroscience clinical trials center could bring treatments to patients faster
6. 2011 ASH Annual Meeting to highlight latest hematology research, clinical care breakthroughs
7. BMC resident receives American Society for Clinical Pathology awards
8. First whole-genome sequencing clinical trials for triple-negative breast cancer presented
9. Researchers validate preclinical effectiveness of TB drug target
10. Use of retail medical clinics rises 10-fold over 2-year period, study finds
11. AAOS issues new clinical practice guideline for treating common elbow fractures in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate ... in 2017 who are passionate about making a difference in the lives of ... in Tampa, UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance ... commercial and residential clients in the California Bay Area, is launching a charity drive ... the region. , Heart disease is the primary killer of adult men and women ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Tribble Insurance ... to the eastern Virginia region, is inaugurating a charity event to honor Chad Phillip ... While on duty last year, Chad Phillip Dermyer and his fellow officers were conducting ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... St. Catherine’s ... Center. , Siena Center is a skilled nursing facility on the grounds of the ... semiprivate rooms. It recently was voted the best nursing home in Mississippi for the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017 The Global ... understanding and access to partnering deals and agreements entered ... Trends in partnering deals - Top deals by value ... of development, technology type The report provides understanding ... into by the world,s leading healthcare companies. The ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... "Breast Imaging Technologies Market by Type: Global Opportunity Analysis and ... market size was valued at $2,544 million in 2015 and ... a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. Ionizing ...
Breaking Medicine Technology: